Most Recent
Otsuka can press ahead with ‘inconsistent’ defences in Abilify patent dispute
Intellectual Property 2019-02-27 8:38 pm By Miklos Bolza

Otsuka Pharmaceuticals and Bristol Myers-Squibb can retain their defences in an ongoing patent dispute over antipsychotic drug Abilify, after the Federal Court dismissed a strike […]

Subscribe for instant access to all Lawyerly content.

Already a subscriber?

Lost your password?

Want to test drive Lawyerly? Contact us to take a free trial.